This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent
124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or
myeloma) and/or Alzheimer's disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center Samus Therapeutics, Inc.
Collaborators:
Memorial Sloan Kettering Cancer Center Rockefeller University Weill Medical College of Cornell University